McKesson Corporation $MCK Holdings Increased by James Hambro & Partners LLP

James Hambro & Partners LLP raised its position in McKesson Corporation (NYSE:MCK) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 138,952 shares of the company’s stock after purchasing an additional 4,301 shares during the period. McKesson accounts for 4.1% of James Hambro & Partners LLP’s investment portfolio, making the stock its 11th biggest position. James Hambro & Partners LLP’s holdings in McKesson were worth $118,760,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nvwm LLC boosted its stake in McKesson by 933.3% during the third quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 28 shares during the period. Delos Wealth Advisors LLC bought a new stake in shares of McKesson during the 2nd quarter valued at about $27,000. Clearstead Trust LLC purchased a new position in shares of McKesson during the second quarter worth about $37,000. GK Wealth Management LLC purchased a new position in shares of McKesson during the third quarter worth about $38,000. Finally, Bell Investment Advisors Inc bought a new position in shares of McKesson in the second quarter worth approximately $39,000. Institutional investors own 85.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company lifted their target price on shares of McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Argus raised their price objective on shares of McKesson from $850.00 to $970.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Morgan Stanley set a $977.00 price objective on shares of McKesson in a report on Tuesday, October 6th. Leerink Partners lifted their price objective on shares of McKesson from $1,030.00 to $1,070.00 and gave the stock an “outperform” rating in a report on Wednesday, October 7th. Finally, Barclays lifted their price target on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $990.35.

Insider Transactions at McKesson

In other news, Director Bradley Lerman sold 301 shares of McKesson stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO B Jr sold 111 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the sale, the chief accounting officer directly owned 521 shares of the company’s stock, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.06% of the stock is currently owned by company insiders.

McKesson Stock Down 0.1%

Shares of McKesson stock traded down $0.82 during trading on Monday, reaching $1,004.02. The company’s stock had a trading volume of 237,748 shares, compared to its average volume of 927,037. McKesson Corporation has a 52-week low of $723.68 and a 52-week high of $1,014.99. The company has a market cap of $117.06 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 2.00 and a beta of 0.30. The firm’s 50-day moving average is $897.66 and its two-hundred day moving average is $837.34.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, topping analysts’ consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion for the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm’s revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the company earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, equities research analysts anticipate that McKesson Corporation will post 44.71 EPS for the current year.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date of this dividend was Tuesday, September 1st. McKesson’s payout ratio is 10.06%.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.